

**In the Specification**

Please amend the specification as follows. Applicant has included herewith an amended paragraph of the specification with insertions and deletions indicated by bracketing and strikethrough, respectively. To avoid confusion, underlining is not utilized to indicate insertions because there are underlined sections in the paragraph as filed.

At page 4, line 11:

One key methodology is described by Sahin, et al., Proc. Natl. Acad. Sci. USA 92: 11810-11913 (1995), incorporated by reference. Also, see U.S. Patent Applications Serial No. [6,025,191, issued Feb. 15, 2000] 08/580,980, and [U.S. Patent 5,698,396, issued Dec. 16, 1997]~~Application Serial No. 08/479,328, filed on June 7, 1995 and January 3, 1996, respectively.~~ All three of these references are incorporated by reference. To summarize, the method involves the expression of cDNA libraries in a prokaryotic host. (The libraries are secured from a tumor sample). The expressed libraries are then immunoscreened with absorbed and diluted sera, in order to detect those antigens which elicit high titer humoral responses. This methodology is known as the SEREX method (“Serological identification of antigens by Recombinant Expression Cloning”). The methodology has been employed to confirm expression of previously identified tumor associated antigens, as well as to detect new ones. See the above referenced patent applications and Sahin, et al., supra, as well as Crew, et al., EMBO J 144:2333-2340(1995).